Isis, J&J Ink Diabetes Drug Deal

 

Isis Pharmaceuticals(ISIS) announced a collaboration Thursday with Johnson & Johnson's (JNJ) Ortho-McNeil, to develop and market drugs for metabolic diseases such as type II diabetes and obesity.

The partnership garners Isis a $45 million licensing fee upfront and as much as $230 million more in milestone payments.

Ortho-McNeil will fund the joint effort, and Isis is granting Ortho-McNeil worldwide development and commercialization rights to two of its diabetes development candidates, ISIS 325568 and ISIS 377131.

After the collaboration phase, J&J's Pharmaceutical Research & Development will continue development of the drugs, which are designed to selectively inhibit the production of glucagon receptor (GCGR) and glucocorticoid receptor (GCCR).

Isis is eligible for royalties on sales should the two products come to market, and it may also receive milestones and royalties for additional drugs discovered in association with the collaboration.

Isis said it will purchase the equity in Symphony GenIsis before closing the transaction with OrthoMcNeil and reacquire the intellectual property related to the GCGR and GCCR programs as well as regain full ownership of lipid-lowering drug ISIS 301012. Isis previously licensed the above to Symphony GenIsis for $75 million with the right to buy back all of the intellectual property involved.

Isis shares climbed 79 cents, or 6.2%, to $13.55, while J&J edged up 60 cents, or 0.9%, to $63.10.

>To order reprints of this article, click here: Reprints

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,801.23 1,342.64 2,903.88 19.69
Oil *
117.67
DOWN
89.23
DOWN
9.31
DOWN
23.35
DOWN
0.78
10 Yr
1.97%
SPDR Gold
167.14
-0.69%
-0.69%
-0.80%
-3.81%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet